Ultime notizie per ProQR Therapeutics (NASDAQ:PRQR) Azioni

ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV

Biotech

General

PRQR

ProQR Submits Clinical Trial Application To EMA To Initiate Phase 1 Trial Of AX-0810 Targeting NTCP

Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform and lowers the price target from $15 to $9.

News

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9

Earnings

Earnings Beats

Earnings Misses

ProQR Therapeutics Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $4.75M Beat $4.49M Estimate

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform rating and announces Price Target of $5.

Initiation

Evercore ISI Group Initiates Coverage On ProQR Therapeutics with Outperform Rating, Announces Price Target of $5

Management

ProQR Names Dennis Hom As CFO

LEIDEN, Netherlands &amp; CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer&#x2122; RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage.

ProQR Therapeutics Appoints Dennis Hom As CFO

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $4 price target.

Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $10 to $12.

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $12

The company said € 149.4 million cash and cash equivalents as of end of 2024, providing runway into mid-2027, plus additional potential milestones from Lilly partnership.

ProQR FY24 EPS EUR(0.32) Up From EUR(0.35) YoY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>DA Davidson analyst Gil Luria initiated coverage on Blaize Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) with a Buy rating and announced a price target of $10. Blaize shares closed at $3.21 on Tuesday. <a href="https://www.benzinga.com/quote/BZAI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Catherine Novack initiated coverage on ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy rating and announced a price target of $11. ProQR Therapeutics shares closed at $2.19 on Tuesday. <a href="https://www.benzinga.com/quote/PRQR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Tom Nikic initiated coverage on Ralph Lauren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Buy rating and announced a price target of $310. Ralph Lauren shares closed at $272.17 on Tuesday. <a href="https://www.benzinga.com/quote/RL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Aaron Kessler initiated coverage on Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Buy rating and announced a price target of $62. Maplebear shares closed at $49.69 on Tuesday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Tom Nikic initiated coverage on V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Buy rating and announced a price target of $28. VF shares closed at $24.35 on Tuesday. <a href="https://www.benzinga.com/quote/VFC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying RL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12085206/image-104-1024x574.png" alt="" class="wp-image-778742" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12085206/image-104-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12085206/image-104-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12085206/image-104-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12085206/image-104.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

BZAI

CART

This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Jones Trading analyst Catherine Novack initiates coverage on ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy rating and announces Price Target of $11.

Jones Trading Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $11

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

Reiteration

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $10 Price Target

ProQR Therapeutics NV. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer&#x2122; RNA editing technology platform, today announced an expansion of its collaboration with the Rett Syndrome Research Trust (RSRT). Building on the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Dsx1RiYqkjHBqb-lIkrSz2noMHoflfEI6btUa5AtkqPvx44ToZUwX37L-qvo05YjUcobTuHcv2m6m80srRqEsejWR4fwMwJ6Qz9UTOOd-lJGLyUF_8EQqBLN8nx_nvgxX19EI-ejBu2ocglEdDjMEaESNxXEnBl7A7SxsWJpeaJ53yHbZYFWqpddNu56USLp8n2l5UV9ZjYb328G6vb1zWJftnlabPl6YZZstTfVX1WQVALgNUUOr5qVK6XaRA_SV0RSXz1cHqWFLfKic6qEmfND5naYM3qrO1MJXTPkhMg=">initial $1 million research grant announced in January 2024</a>,&nbsp;the expanded partnership includes an additional $8.1 million in funding from the RSRT, for a total of $9.1 million. The funding will support the advancement of AX-2402 into clinical trials.
Rett Syndrome, a rare and devastating neurodevelopmental disorder, affects approximately 350,000 people worldwide, predominantly girls. With no current cures and limited treatment options, Rett Syndrome presents a significant unmet medical need. AX-2402 is being developed for individuals with Rett syndrome who have the R270X mutation in MECP2 gene, and is based on ProQR's proprietary Axiomer RNA editing platform. Axiomer can target many mutations beyond R270X that collectively impact a large segment of the Rett population. Success with AX-2402 sets the foundation for developing RNA editing therapeutics to target the remaining mutations.

ProQR Receives $9.1M to Develop RNA Therapy for Rett Syndrome, Impacting 350,000 People

U.S. stock futures were mixed this morning, with the Dow futures falling more than 100 points on Monday.
Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) fell sharply in today's pre-market trading after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett <a href="https://www.benzinga.com/quote/NGNE">syndrome patient</a>.
Neurogene shares declined 37.7% to $21.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares tumbled 16.1% to $2.29 in pre-market trading after dipping over 20% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares dipped 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) tumbled 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares fell 7% to $6.28 in pre-market trading.</li>
<li>CompoSecure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) shares declined 5.9% to $13.00 in pre-market trading.</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares fell 5.4% to $266.21 in pre-market trading following a 4% decline on Friday.</li>
<li>Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) shares fell 5% to $11.80 in pre-market trading after jumping 21% on Friday.</li>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares fell 4% to $3.67 in pre-market trading.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell 2.4% to $138.51 in pre-market trading after declining more than 3% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

Movers

AMAT

AMGN

CMPO

LAZR

LUNR

NGNE

NVDA

OMER

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

WIIM

ProQR Therapeutics shares are trading higher afer HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $10.

HC Wainwright &amp; Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Buy and raises the price target from $5 to $10.

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $10

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Renata Cabral upgraded the rating for Coca-Cola FEMSA, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) from Neutral to Buy and raised the price target from $93 to $102. Coca-Cola Femsa shares closed at $84.40 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Sean Milligan upgraded the rating for First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) from Neutral to Buy and announced a $260 price target. First Solar shares closed at $205.03 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dormois upgraded Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) from Underperform to Hold. Philips shares closed at $26.62 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Outperform to Strong Buy and boosted the price target from $6 to $14. ProQR Therapeutics shares closed at $3.31 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Adam Seiden upgraded the rating for Summit Materials, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) from Equal-Weight to Overweight and raised the price target from $45 to $52. Summit Materials shares closed at $45.63 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying FSLR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-1024x534.png" alt="" class="wp-image-619521" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/29094905/image-301.png 1217w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41598310/jim-cramer-avoid-this-consumer-cyclical-stock-buy-lam-research">Jim Cramer: &#8216;Avoid&#8217; This Consumer Cyclical Stock, Buy Lam Research</a></li>
</ul>

Upgrades

FSLR

This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Raymond James analyst Steven Seedhouse upgrades ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) from Outperform to Strong Buy and raises the price target from $6 to $14.

Comments

ProQR Therapeutics

Notizie

Ultime notizie per ProQR Therapeutics (NASDAQ:PRQR) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO